There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.